Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies

Nikita Pozdeyev; Minjae Yoo; Ryan Mackie; Rebecca E. Schweppe; Aik Choon Tan; Bryan R. Haugen

doi:10.18632/oncotarget.10010

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies

Nikita Pozdeyev _, Minjae Yoo, Ryan Mackie, Rebecca E. Schweppe, Aik Choon Tan and Bryan R. Haugen

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:51619-51625. https://doi.org/10.18632/oncotarget.10010

Metrics: PDF 3094 views | HTML 4541 views | ?

Abstract

Nikita Pozdeyev1, Minjae Yoo1, Ryan Mackie1, Rebecca E. Schweppe1, Aik Choon Tan1,*, Bryan R. Haugen1,*

1Department of Medicine, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA

*Two senior authors contributed equally to this work

Correspondence to:

Nikita Pozdeyev, email: [email protected]

Keywords: database integration, drug sensitivity, pharmacogenomics, cancer, cell line

Received: April 08, 2016 Accepted: May 29, 2016 Published: June 14, 2016

ABSTRACT

The consistency of in vitro drug sensitivity data is of key importance for cancer pharmacogenomics. Previous attempts to correlate drug sensitivities from the large pharmacogenomics databases, such as the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC), have produced discordant results. We developed a new drug sensitivity metric, the area under the dose response curve adjusted for the range of tested drug concentrations, which allows integration of heterogeneous drug sensitivity data from the CCLE, the GDSC, and the Cancer Therapeutics Response Portal (CTRP). We show that there is moderate to good agreement of drug sensitivity data for many targeted therapies, particularly kinase inhibitors. The results of this largest cancer cell line drug sensitivity data analysis to date are accessible through the online portal, which serves as a platform for high power pharmacogenomics analysis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10010

Publication Alerts

Research Papers:

Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies

Abstract